Eugene Mangieri, MD
Pain Medicine · Northport, ALNPI 1063513885
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 392 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 38 manufacturers, the largest accounting for just 20.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2020 at $1,259 and has fallen 53.2% since, to $590 in 2025.
Across 392 payments — averaging $16.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$1K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
- Forte Bio-pharma LLC$981
- AstraZeneca$476
- Collegium Pharmaceutical, Inc.$444
- Novo Nordisk$415
- plus $2K from 32 others
What the payments were for
- Food & beverage$6,631100%
- Education$260%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,657 in reported general payments places this provider in the 80th percentile of 77 pain medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 138 | $174,062 |
| OzempicSemaglutide | 124 | $132,851 |
| OxycontinOxycodone Hcl | 48 | $126,881 |
| RexultiBrexpiprazole | 64 | $102,162 |
| Levorphanol Tartrate | 19 | $75,504 |
| FarxigaDapagliflozin Propanediol | 86 | $58,696 |
| ProlateOxycodone Hcl/Acetaminophen | 26 | $57,547 |
| RelistorMethylnaltrexone Bromide | 25 | $57,399 |
| Xtampza ErOxycodone Myristate | 50 | $56,659 |
| MounjaroTirzepatide | 42 | $44,193 |
| Methadone Hcl | 1,085 | $36,624 |
| LinzessLinaclotide | 50 | $27,518 |
| Nucynta ErTapentadol Hcl | 13 | $24,034 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 89 | $18,125 |
| Nurtec OdtRimegepant Sulfate | 14 | $16,874 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $415 | $132,851124 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $1,376 | $102,16264 claims |
| Collegium Pharmaceutical, Inc.Xtampza Er, Nucynta Er, Belbuca | $444 | $91,67682 claims |
| Virtus Pharmaceuticals LLCLevorphanol Tartrate | $102 | $75,50419 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor, Trulance | $1,014 | $67,16443 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $476 | $65,43797 claims |
| Forte Bio-pharma LLCProlate | $981 | $57,54726 claims |
| Lilly USA, LLCMounjaro | $16 | $44,19342 claims |
| AbbVieLinzess | $55 | $27,51850 claims |
| Hikma Pharmaceuticals USABuprenorphine-Naloxone, Buprenorphine | $21 | $21,219101 claims |
| PfizerNurtec Odt | $158 | $16,87414 claims |
| Redhill Biopharma Inc.Movantik | $12 | $15,57237 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 77 pain medicine providers in Alabama.
Other pain medicine in Northport
- Christopher PaulBirmingham$64K
- Michael CosgroveHuntsville$25K
- Ron PitkanenMountain Brk$16K
- Elliott PenningtonDaphne$15K
- James ThackerHuntsville$13K
- Grant StoneMobile$11K
- Hayden HundleyDothan$11K
- Hugh MaddoxAnniston$10K
- Jeremy BarlowVestavia Hills$9K
- Nitin ChhabraHoover$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.